Purpose
To compare the relationship between prostaglandin analogs (PGAs) versus non-prostaglandin analog glaucoma medications on SLT outcome.
Methods
A retrospective chart review of 25 eyes of 25 patients who underwent SLT. All patients were on either 1 PGA medication (latanoprost 0.005% or bimatoprost 0.03%) or 1 non-PGA medication (timolol 0.5%, brimonidine 0.2%, or dorzolamide 2%). Mean intraocular pressure (IOP) was measured before SLT and up to 2 years after SLT.
Results
The patient demographics and results are summarized in Tables 1 and 2 respectively. Baseline mean IOP was 17.7+/-2.5 mmHg for PGA users and 20.1+/-3.1 mmHg for non-PGA users. For PGA users, mean IOP was 16.3+/-5.6 mmHg (p=0.6), 14.3+/-1.7 mmHg (p=0.04), and 12.5+/-1.9 mmHg (p=0.006) at 9-12 months, 21-24 months, and 24-30 months after SLT respectively. For non-PGA users, mean IOP was 14.8+/-3.1 mmHg (p=0.002), 13.3+/-4.2 mmHg (p=0.0004), and 14.6+/-4.0 mmHg (p=0.0009) at 9-12 months, 21-24 months, and 24-30 months after SLT respectively. Mean IOP for PGA users versus non-PGA users was compared at 9-12 months (p=0.6), 21-24 months (p=0.7), and 24-30 months (p=0.3).
Conclusions
Patients using PGAs had a statistically significant reduction in mean IOP 21-24 months and 24-30 months after SLT. Patients using non-PGAs had a statistically significant reduction in mean IOP at 9-12 months, 21-24 months, and 24-30 months after SLT. There was no statistically significant difference in mean IOP between PGA users and non-PGA users at each time point.
Keywords: 578 laser •
568 intraocular pressure